Welcome to the Valeant Pharmaceuticals Fair Fund Website

This website has been established to provide general information related to the Valeant Pharmaceuticals Fair Fund, the Fair Fund established in the United States Securities and Exchange Commission ("SEC" or “Commission”) Proceedings.

The administration of the Fair Fund is governed by the Corrected Plan of Distribution (the “Plan”) which was approved by the Commission on August 22, 2024.  A copy of the approved Plan, which contains a description of eligibility and other conditions of participation, can be found on the Case Documents tab of this website. 

The Plan provides for the distribution of a Fair Fund (the “Fair Fund”), comprised of civil money penalties paid by Valeant Pharmaceuticals International, Inc. n/k/a Bausch Health Companies (“Valeant”); J. Michael Pearson (“Pearson”); Howard B. Schiller (“Schiller”); and Tanya R. Carro, CPA (“Carro”) (collectively, the “Respondents”).  

The Fair Fund was established by the Commission to compensate investors who were harmed by the Respondents’ conduct described in the Orders instituted against Respondents.  Respondents paid a collective total of $45,425,000, which is available for distribution to harmed investors.

If you purchased or otherwise acquired Valeant common stock or bonds between October 20, 2014 and April 28, 2016, inclusive, for investors in Valeant common stock or between October 20, 2014 and October 29, 2015, inclusive, for investors in Valeant bonds listed in Table C of the Plan of Allocation (the “Relevant Period”), you may be eligible for a distribution from the Fair Fund, subject to other provisions of the Plan. 

Please review the Plan Notice in full (available on the Case Documents tab of this website) to determine if and how you can make a claim.

To view the SEC Harmed Investor page, please use the following link:  https://www.sec.gov/enforce/valeant-pharmaceuticals-intl-inc